1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Primary outcomea
10-Caliber Coils (n = 106)15-Caliber Coils (n = 104)
Primary outcome met36 (34.0%)37 (35.6%)
 Major recurrence20 (18.9%)26 (25.0%)
 Retreatment4 (3.8%)4 (3.8%)
 Initial treatment failure6 (5.7%)4 (3.8%)
 SAH1 (0.9%)0
 Related mortality5 (4.7%)2 (1.9%)
 Related morbidity01 (1.0%)
Good outcome64 (60.4%)64 (61.5%)
Not attributed6 (5.7%)3 (2.9%)
 Lost to follow-up4 (3.8%)3 (2.9%)
 Unrelated mortality2 (1.9%)0
  • ↵a No significant difference between groups was found in the primary outcome. Data are (No.) (%).